Jungwook Chin

Jungwook Chin

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TSThoudam Debraj Singh
Thoudam Debraj Singh
JSJaeyoung Song
Jaeyoung Song
JKJina Kim
Jina Kim
JCJungwook Chin
Jungwook Chin
HJHyun Dong Ji
Hyun Dong Ji
YJYong Hyun Jeon
Yong Hyun Jeon
Purpose: New strategies to restore sodium iodide symporter (NIS) expression and function in radioiodine therapy-refractive anaplastic thyroid cancers (ATCs) are urgently required. Recently, we reported the regulatory role of estrogen-related receptor gamma (ERRγ) in ATC cell NIS function. Herein, we identified DN200434 as a highly potent (functional IC50 = 0.006 μM), selective, and orally available ERRγ inverse agonist for NIS enhancement in ATC. Experimental Design: We sought to identify better ERRγ-targeting ligands and explored the crystal structure of ERRγ in complex with DN200434. After treating ATC cells with DN200434, the change in iodide-handling gene expression as well as radioiodine avidity was examined. ATC tumor-bearing mice were orally administered with DN200434, followed by 124I-positron emission tomography/computed tomography (PET/CT). For radioiodine therapy, ATC tumor-bearing mice treated with DN200434 were administered 131I (beta ray-emitting therapeutic radioiodine) and then bioluminescent imaging was performed to monitor the therapeutic effects. Histological analysis was performed to evaluate ERRγ expression status in normal tissue and ATC tissue, respectively. Results: DN200434-ERRγ complex crystallographic studies revealed that DN200434 binds to key ERRγ binding pocket residues through four-way interactions. DN200434 effectively upregulated iodide-handling genes and restored radioiodine avidity in ATC tumor lesions, as confirmed by 124I-PET/CT. DN200434 enhanced ATC tumor radioiodine therapy susceptibility, markedly inhibiting tumor growth. Histological findings of patients with ATC showed higher ERRγ expression in tumors than in normal tissue, supporting ERRγ as a therapeutic target for ATC. Conclusions: DN200434 shows potential clinical applicability for diagnosis and treatment of ATC or other poorly differentiated thyroid cancers.

20 November 2018 in Organic Letters
Verified
Journal Article
Closed access
GKGeum Jin Kim
Geum Jin Kim
XLXian Li
Xian Li
SKSeong-Hwan Kim
Seong-Hwan Kim
IYInho Yang
Inho Yang
DHDongyup Hahn
Dongyup Hahn
HCHyukjae Choi
Hyukjae Choi

15 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKTara Man Kadayat
Tara Man Kadayat
ASAarajana Shrestha
Aarajana Shrestha
YJYong Hyun Jeon
Yong Hyun Jeon
HAHongchan An
Hongchan An
JKJina Kim
Jina Kim
JCJungwook Chin
Jungwook Chin

7 September 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAarajana Shrestha
Aarajana Shrestha
NKNayeon Kim
Nayeon Kim
SLSu-Jeong Lee
Su-Jeong Lee
YJYong Hyun Jeon
Yong Hyun Jeon
JSJi-Joon Song
Ji-Joon Song
JCJungwook Chin
Jungwook Chin

9 November 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JKJina Kim
Jina Kim
SWSeo Yeon Woo
Seo Yeon Woo
CIChun Young Im
Chun Young Im
EYEun Kyung Yoo
Eun Kyung Yoo
SLSeungmi Lee
Seungmi Lee
SCSung Jin Cho
Sung Jin Cho

18 January 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JKJina Kim
Jina Kim
JSJaeyoung Song
Jaeyoung Song
HJHyun Dong Ji
Hyun Dong Ji
EYEun Kyung Yoo
Eun Kyung Yoo
JLJae-Eon Lee
Jae-Eon Lee
SCSung Jin Cho
Sung Jin Cho